Dapagliflozin and Urinary Tract Infection Risk in Type 2 Diabetes: A Comprehensive Critical Review of Mechanistic, Randomized, and Real-World Evidence. Trop. j. pharm. life sci. [Internet]. 2026 Oct. 30 [cited 2026 Nov. 1];13(5):53-68. Available from: https://informativejournals.com/journal/index.php/tjpls/article/view/342